Home Healthcare Pharmaceuticals Brain Tumor Drugs Market

Brain Tumor Drugs Market Size, Share & Trends Analysis Report By Type (Glioblastoma, Meningioma, Pituitary Tumors, Ependymoma, Medulloblastoma, Others), By Therapy (Chemotherapy Drugs, Immunotherapy Drugs, Cell and Gene Therapy Drugs, Targeted Therapy Drugs, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 29, 2026 | Author: Dhanashri B | Format: | Report Code: SR7884DR | Pages: 220
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Brain Tumor Drugs Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Glioblastoma
    2. Meningioma
    3. Pituitary Tumors
    4. Ependymoma
    5. Medulloblastoma
    6. Others
  2. Brain Tumor Drugs Market, By Therapy 2022-2034 (USD MILLION/ Units)
    1. Chemotherapy Drugs
    2. Immunotherapy Drugs
    3. Cell and Gene Therapy Drugs
    4. Targeted Therapy Drugs
    5. Others
  3. Regional Brain Tumor Drugs Market
    1. North America
      1. North America Brain Tumor Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
      2. North America Brain Tumor Drugs Market By Therapy 2022-2034 (USD MILLION/ Units)
        1. Chemotherapy Drugs
        2. Immunotherapy Drugs
        3. Cell and Gene Therapy Drugs
        4. Targeted Therapy Drugs
        5. Others
      3. U.S.
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      4. Canada
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
    2. Europe
      1. Europe Brain Tumor Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
      2. Europe Brain Tumor Drugs Market By Therapy 2022-2034 (USD MILLION/ Units)
        1. Chemotherapy Drugs
        2. Immunotherapy Drugs
        3. Cell and Gene Therapy Drugs
        4. Targeted Therapy Drugs
        5. Others
      3. U.K.
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      4. Germany
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      5. France
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      6. Spain
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      7. Italy
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      8. Russia
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      9. Nordic
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      10. Benelux
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      11. Rest of Europe
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
    3. APAC
      1. APAC Brain Tumor Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
      2. APAC Brain Tumor Drugs Market By Therapy 2022-2034 (USD MILLION/ Units)
        1. Chemotherapy Drugs
        2. Immunotherapy Drugs
        3. Cell and Gene Therapy Drugs
        4. Targeted Therapy Drugs
        5. Others
      3. China
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      4. Korea
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      5. Japan
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      6. India
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      7. Australia
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      8. Taiwan
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      9. South East Asia
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      10. Rest of Asia-Pacific
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
    4. Middle East and Africa
      1. Middle East and Africa Brain Tumor Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
      2. Middle East and Africa Brain Tumor Drugs Market By Therapy 2022-2034 (USD MILLION/ Units)
        1. Chemotherapy Drugs
        2. Immunotherapy Drugs
        3. Cell and Gene Therapy Drugs
        4. Targeted Therapy Drugs
        5. Others
      3. UAE
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      4. Turkey
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      5. Saudi Arabia
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      6. South Africa
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      7. Egypt
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      8. Nigeria
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      9. Rest of MEA
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
    5. LATAM
      1. LATAM Brain Tumor Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
      2. LATAM Brain Tumor Drugs Market By Therapy 2022-2034 (USD MILLION/ Units)
        1. Chemotherapy Drugs
        2. Immunotherapy Drugs
        3. Cell and Gene Therapy Drugs
        4. Targeted Therapy Drugs
        5. Others
      3. Brazil
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      4. Mexico
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      5. Argentina
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      6. Chile
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      7. Colombia
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
      8. Rest of LATAM
        1. Glioblastoma
        2. Meningioma
        3. Pituitary Tumors
        4. Ependymoma
        5. Medulloblastoma
        6. Others
        7. Chemotherapy Drugs
        8. Immunotherapy Drugs
        9. Cell and Gene Therapy Drugs
        10. Targeted Therapy Drugs
        11. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.